Department of General Surgery, The Fourth Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, China.
Microvasc Res. 2018 Nov;120:21-28. doi: 10.1016/j.mvr.2018.05.007. Epub 2018 May 17.
Deep vein thrombosis (DVT) is a severe clinical process and has a high rate of fatality. Cancer patients have a high incidence rate of venous thrombosis complication and increase the mortality of cancer patients for 2-8 times. The mechanisms involved in human cancers and venous thrombosis remains unclear. In this study, we determined miR-21 expressed higher in human breast cancer, colon cancer and hepatocellular cancer tissues compared with normal tissues and expressed higher in exosomes of breast cancer and hepatocellular cancer cell lines compared with normal cells. MiR-21 dramatically suppressed proliferation, migration and invasion of endothelial progenitor cells (EPCs), which performed promoting role in thrombus repairment and resolution. High levels of miR-21 in exosomes of human cancers dramatically inhibited behaviors of EPCs, and depletion of miR-21 abrogated the decreased proliferation, migration and invasion of EPCs induced by human cancer cells. Moreover, IL6R (interleukin 6 receptor) was identified to be a direct target of miR-21 and promoted cell proliferation, migration and invasion of EPCs. Therefore, the miR-21-IL6R pathway contributed to behaviors of EPCs and consequently mediated the vein thrombosis in patients with cancer. MiR-21-IL6R pathway based therapeutic methods would be beneficial to decrease the complicated venous thrombosis in cancer patients and promote thrombus resolution.
深静脉血栓形成(DVT)是一种严重的临床过程,死亡率很高。癌症患者静脉血栓并发症的发生率很高,使癌症患者的死亡率增加 2-8 倍。涉及人类癌症和静脉血栓形成的机制尚不清楚。在这项研究中,我们确定 miR-21 在人乳腺癌、结肠癌和肝癌组织中的表达高于正常组织,并且在乳腺癌和肝癌细胞系的外泌体中的表达高于正常细胞。miR-21 显著抑制内皮祖细胞(EPCs)的增殖、迁移和侵袭,在血栓修复和溶解中发挥促进作用。人癌症外泌体中高水平的 miR-21 显著抑制 EPCs 的行为,而 miR-21 的耗竭消除了人癌细胞诱导的 EPCs 增殖、迁移和侵袭减少。此外,IL6R(白细胞介素 6 受体)被鉴定为 miR-21 的直接靶标,并促进 EPCs 的细胞增殖、迁移和侵袭。因此,miR-21-IL6R 通路参与了 EPCs 的行为,进而介导了癌症患者的静脉血栓形成。基于 miR-21-IL6R 通路的治疗方法将有助于减少癌症患者复杂的静脉血栓形成,并促进血栓溶解。